PR

MEZOO, connecting health through technology
Sharing MEZOO’s technology and vision.
External
2026.10.30
MEZOO Reports 164% Revenue Growth in Q3, Returns to Operating Profitability

[Seoul Economic TV = Lee Seul-bi] MEZOO, a wearable medical device company, successfully returned to operating profitability in the third quarter of 2026, with revenue more than doubling compared to the same period last year.
 

According to a regulatory filing released on October 29, MEZOO reported preliminary standalone revenue of KRW 6.098 billion and an operating profit of KRW 2.092 billion for the third quarter of 2026.
 

Revenue increased by 163.6% year-over-year, while operating profit turned positive from an operating loss of KRW 734 million in the third quarter of the previous year.
 

The company also demonstrated strong performance improvement compared to the previous quarter. Revenue increased by 7.6% quarter-over-quarter, while operating profit surged by 139.1%. The operating profit margin reached approximately 34.3%.
 

However, third-quarter net income stood at KRW 2.303 billion, representing a 55.0% decrease compared to the same period last year.
 

Source: https://www.sentv.co.kr/article/view/sentv202610290212


적용 법률 및 규정
의료기기

하이카디® 시스템은 인허가에 따라 신생아, 소아, 청소년, 18세 이상 환자의 ECG 데이터를 측정하여 부정맥을 진단하는 의료기기로서 의료전문가가 사용하도록 설계되었습니다. 한국 KFDA로부터 의료기기 2등급 인증을 받았습니다. 유럽의료기기 지침(2007/47/EC에 따라 개정된 MDD 93/42/EEC)에 따라 준수된 Class IIb (CE2265). 의료기기 제품으로 CE 승인되었습니다. 미국 FDA는 Class II 510K로 승인 완료 예정입니다.

경고

본 자료는 의료 전문가에게만 배포되며 관련 사진과 함께 제공되는 자료와 관련하여 그 어떤 법적인 책임을 갖지 않습니다. 사용 전 사용 지침서를 주의 깊게 읽으십시오.